Vincerx Pharma, INC 8-K filings

Vincerx Pharma, Inc. is proceeding with its dissolution and liquidation, urging stockholders to approve the plan to facilitate an estimated distribution of $0.04 to $0.08 per share and potential tax benefits.

Vincerx Pharma plans to delist from Nasdaq, dissolve the company, and liquidate its assets after failing to meet the minimum bid price requirement.

Vincerx Pharma has terminated its merger agreement with QumulusAI and is initiating wind-down activities while exploring asset monetization.

Vincerx Pharma has entered a non-binding letter of intent to merge with QumulusAI, a high-performance computing infrastructure company for artificial intelligence, in a reverse triangular merger.

Vincerx Pharma has terminated its reverse merger term sheet with Oqory, Inc. and is now evaluating strategic alternatives, including a potential wind-down of operations.

Vincerx Pharma has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement of $1.00 per share.

Vincerx Pharma and Oqory, Inc. amend their merger term sheet, increasing the minimum value for Vincerx stockholders to $14.16 million and waiving the remaining $500,000 interim financing.

Vincerx Pharma and Oqory, Inc. have entered into a binding term sheet for a proposed merger, aiming to create a combined company focused on advancing antibody-drug conjugate (ADC) therapies.

Vincerx Pharma will implement a 1-for-20 reverse stock split, effective January 27, 2025, to maintain its Nasdaq listing.

Vincerx Pharma enters into a sales agreement for a $30 million at-the-market offering while also disclosing a binding term sheet for a potential business combination with Oqory, a private biopharmaceutical company.

Vincerx Pharma terminated its sales agreement with Leerink Partners and approved a reverse stock split at a special meeting of stockholders.

Vincerx Pharma plans to merge with Oqory, Inc., adding a Phase 3 TROP2 ADC to its pipeline, with Oqory equity holders expected to own 95% of the combined entity.

Vincerx Pharma is implementing a 55% workforce reduction and exploring strategic alternatives, including potential mergers or asset sales, to support the advancement of its VIP943 Phase 1 study.

Vincerx Pharma has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, extending the deadline to May 19, 2025.

Vincerx Pharma announced its third quarter 2024 financial results and provided updates on its clinical programs, highlighting positive data from its VIP943 antibody-drug conjugate.

Vincerx Pharma reports promising clinical data for its drug candidates VIP943, VIP236, and enitociclib, and plans to seek strategic partners for VIP236 and enitociclib development.

Vincerx Pharma's board and stockholders approved a stock option repricing program, lowering the exercise price for underwater options to $0.55 per share, contingent on continued employment.

Vincerx Pharma announced its second quarter 2024 financial results, highlighting progress in clinical trials and a strengthened cash position.

Vincerx Pharma received a notice from Nasdaq for failing to meet the minimum bid price requirement and has amended its bylaws to adjust quorum and meeting procedures.

Vincerx Pharma announced its first quarter 2024 financial results and provided updates on its clinical programs, including progress in Phase 1 dose-escalation studies for its drug candidates.

Vincerx Pharma has priced a public offering to raise approximately $16.5 million through the sale of common stock, pre-funded warrants, and accompanying common stock warrants.

Vincerx Pharma has announced a public offering of common stock and warrants to raise capital, following a recent at-the-market offering and a decrease in cash reserves.

Vincerx Pharma presented positive preliminary Phase 1 data for VIP236 and provided an update on pipeline progress at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Vincerx Pharma has entered into a sales agreement with Leerink Partners to potentially sell up to $50 million of its common stock through an at-the-market offering.

Vincerx Pharma announced its 2023 financial results, highlighting progress in its clinical programs and providing a corporate update, including upcoming presentations of clinical data.

Vincerx Pharma has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement.